CHELMSFORD, Mass., April 29, 2019 /PRNewswire/ -- Brooks
Automation, Inc. (Nasdaq: BRKS) today reported financial results
for the second fiscal quarter of 2019, ended March 31, 2019.
|
|
Financial Results
Summary
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter Ended
|
|
|
|
|
|
|
|
Dollars in millions, except per share
data
|
|
March 31,
|
|
December
31,
|
|
|
March 31,
|
|
Change
vs.
|
|
|
|
|
|
2019
|
|
2018
|
|
|
2018
|
|
Prior
Qtr
|
|
Prior
Year
|
|
|
|
Revenue
|
|
$
|
198
|
|
$
|
179
|
|
|
$
|
157
|
|
11
|
%
|
26
|
%
|
|
|
Semiconductor Solutions
Group
|
|
$
|
113
|
|
$
|
113
|
|
|
$
|
108
|
|
0
|
%
|
4
|
%
|
|
|
Life
Sciences
|
|
$
|
86
|
|
$
|
67
|
|
|
$
|
49
|
|
28
|
%
|
76
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted EPS
Continuing Operations
|
|
$
|
(0.04)
|
|
$
|
0.09
|
|
|
$
|
0.89
|
|
(145)
|
%
|
(104)
|
%
|
|
|
Diluted EPS
Total
|
|
$
|
0.05
|
|
$
|
0.20
|
|
|
$
|
0.95
|
|
(76)
|
%
|
(95)
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP Diluted EPS
Cont. Operations
|
|
$
|
0.17
|
|
$
|
0.17
|
|
|
$
|
0.18
|
|
3
|
%
|
(3)
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
EBITDA
|
|
$
|
33
|
|
$
|
28
|
|
|
$
|
25
|
|
(18)
|
%
|
29
|
%
|
|
|
|
|
The Company announced on August 27,
2018 it had entered into a definitive agreement to sell its
Semiconductor Cryogenics business to Edwards Vacuum LLC (a member
of the Atlas Copco Group). In accordance with GAAP, the
Company is reporting the operating results of the Semiconductor
Cryogenics business, for all periods presented, as discontinued
operations.
Management Comments
"We are pleased to report solid Q2
operating results with 26% year-over-year revenue growth.
Life Sciences grew 76% while Semiconductor Solutions remained solid
with 4% growth, despite the semiconductor capital equipment slow
down. Our Semiconductor Solutions resilience is a testament
to our product portfolio that serves a broadening customer base
across the range of chip technologies," commented Steve Schwartz, president and CEO. "During our
first full quarter of owning GENEWIZ, that team captured 170 new
customers and continued its revenue growth driven by its
next-generation sequencing and Sanger sequencing
capabilities. Sample Management continued to improve with 11%
year-over-year organic growth. The second quarter results
mark a transformative milestone with 43% of our revenue coming from
Life Sciences."
GAAP Summary, Second Quarter, Fiscal 2019
- Revenue was $198 million in the
second quarter, 11% higher compared to the first fiscal quarter of
2019, and 26% higher compared to the second fiscal quarter of 2018.
Revenue included $33 million from a
full quarter of GENEWIZ that was acquired on November 15, 2018, compared to $16 million in the first quarter.
- GAAP diluted EPS was $0.05
compared with $0.20 in the first
quarter of 2019 and $0.95 in the
second quarter of 2018. Discontinued operations provided
$0.09 and continuing operations
generated a loss of $0.04 per diluted
share, including a $9 million charge
for early extinguishment of debt. The Company syndicated its
$350 million incremental term loan
incurred in connection with the GENEWIZ acquisition.
- GAAP operating income was $14
million, an increase of 156% compared to the first quarter
of 2019 and 32% higher compared with the second quarter of
2018.
- Below operating income, net interest expense increased by
$3 million compared to the first
quarter, due to the full quarter of interest expense associated
with the debt incurred when we acquired GENEWIZ. The Company also
reported a $1 million tax benefit in
the quarter compared to a $6 million
tax benefit last quarter, which had a favorable $0.08 per share impact on EPS in the prior
quarter.
- Life Sciences revenue of $86
million grew 28% compared to the first quarter of 2019. It
was up 76% on a year-over-year basis, inclusive of 11% organic
growth, all attributable to Sample Management. GENEWIZ contributed
$33 million of revenue in the second
quarter, compared to $16 million in
the first quarter.
- Semiconductor Solutions revenue of $113
million, grew 4% on a year over year basis and was flat
compared to the first quarter of 2019.
Non-GAAP Profit Discussion for Continuing Operations
- Non-GAAP diluted EPS from continuing operations for the quarter
was $0.17 compared to $0.17 in the first quarter and $0.18 in the second quarter of 2018. Operating
margins were 12% in the second quarter, expanding 90 basis points
sequentially and 60 basis points year over year on improved gross
margins. The increase in interest expense largely offset the
improved operating income, as the Company raised additional debt in
the middle of the prior quarter to fund the GENEWIZ acquisition.
The Company anticipates paying down a significant portion of
outstanding debt upon closing the sale of the Semiconductor
Cryogenics business.
- Non-GAAP gross margins expanded to 42.0%, an improvement of 60
basis points compared to the first quarter of 2019 and 160 basis
points higher than the second quarter of 2018. Life Sciences gross
margins expanded to 42.6%, up 170 basis points sequentially driven
by 60 basis points improvement in Sample Management and a favorable
mix benefit from additional GENEWIZ revenue. The Semiconductor
Solutions business gross margins were essentially flat sequentially
at 41.6% and were 90 basis points improved compared to the second
quarter of 2018.
- Net interest expense increased $3
million sequentially in the quarter to $8 million reflecting the debt utilized to fund
the GENEWIZ acquisition. The Company expects interest expense to
decrease following an anticipated reduction of debt upon closure of
the sale of the Semiconductor Cryogenics business.
- Adjusted EBITDA in the quarter was $33
million, up from $28 million
in the prior quarter and $25 million
in the second quarter of 2018. The adjusted EBITDA margin expanded
100 basis points sequentially to 16.6% and reflects 40 basis points
improvement from the second quarter of 2018.
- Cash flow from operations was $16
million in the quarter generating $10
million in free cash flow. At March
31, 2019, total debt was $543
million and the balance of cash, cash equivalents, and
marketable securities was $140
million.
A reconciliation of non-GAAP measures to the most nearly
comparable GAAP measures follows the consolidated balance sheets,
statements of operations and statements of cash flows included in
this release.
Pending Sale of the Semiconductor Cryogenics
Business
As previously disclosed, the completion of the sale of the
Company's Semiconductor Cryogenics business is conditioned upon,
among other things, certain regulatory approvals, including the
approval of the Committee on Foreign Investment in the United States (CFIUS). The Company
and the buyer continue to pursue the necessary clearances and
expect that the CFIUS process will conclude in the second calendar
quarter. Accordingly, the Company expects to complete the
sale within the June quarter. The Company and the buyer
remain fully committed to completing the sale as expeditiously as
possible.
Guidance for Fiscal Third Quarter 2019
The
Company announced revenue and earnings guidance for the third
quarter of fiscal 2019. Revenue is expected to be in the
range of $200 million to $210 million and non-GAAP diluted earnings per
share from continuing operations is expected to be in the range of
$0.13 to $0.18. GAAP diluted earnings per share for
the third quarter is expected to be in the range of $0.04 to $0.09.
Quarterly Cash Dividend
The Company
additionally announced that the Board of Directors has reiterated a
dividend of $0.10 per share payable
on June 28, 2019 to stockholders of
record on June 7, 2019. Future
dividend declarations, as well as the record and payment dates for
such dividends, are subject to the final determination of the
Company's Board of Directors.
Conference Call
Brooks management will webcast its
second quarter earnings conference call today at 4:30 p.m. Eastern Time. During the call, Company
management will respond to questions concerning, but not limited
to, the Company's financial performance, business conditions and
industry outlook. Management's responses could contain
information that has not been previously disclosed.
The call will be broadcast live over the Internet and, together
with presentation materials referenced on the call, will be hosted
at the Investor Relations section of Brooks' website at
www.brooks.com, and will be archived online on this website for
convenient on-demand replay. In addition, you may call
800-897-4662 (US & Canada
only) or +1-212-231-2903 for international callers to listen to the
live webcast.
Regulation G – Use of Non-GAAP financial Measures
The
Company supplements its GAAP financial measures with certain
non-GAAP financial measures to provide investors a better
perspective on the results of business operations, which the
Company believes is more comparable to the similar analysis
provided by its peers. These measures are not presented in
accordance with, nor are they a substitute for, U.S. generally
accepted accounting principles, or GAAP. These measures should
always be considered in conjunction with appropriate GAAP measures.
A reconciliation of non-GAAP measures to the most nearly comparable
GAAP measures is included at the end of this release following the
consolidated balance sheets, statements of operations and
statements of cash flows.
Free cash flow is a non-GAAP financial measure and is defined as
operating cash flow minus capital expenditures.
"Safe Harbor Statement" under Section 21E of the Securities
Exchange Act of 1934
Some statements in this release are
forward-looking statements made under Section 21E of the Securities
Exchange Act of 1934. These statements are neither promises nor
guarantees but involve risks and uncertainties, both known and
unknown, that could cause Brooks' financial and business results to
differ materially from our expectations. They are based on the
facts known to management at the time they are made. These
forward-looking statements include, but are not limited to
statements about whether CFIUS will approve the sale of our
Semiconductor Cryogenics business or the expected timing for
completion of the sale, our revenue and earnings expectations, our
ability to increase our profitability, our ability to improve or
retain our market position, the expected financial results from our
recently acquired GENEWIZ business and our ability to deliver
financial success in the future. Factors that could cause results
to differ from our expectations include the following: the
volatility of the industries the Company serves, particularly the
semiconductor industry; our possible inability to meet demand for
our products due to difficulties in obtaining components and
materials from our suppliers in required quantities and of required
quality; the inability of customers to make payments to us when
due; the timing and effectiveness of cost reduction and cost
control measures; price competition; disputes concerning
intellectual property; uncertainties in global political and
economic conditions, the risk that CFIUS does not approve the sale
of the Cryogenics business and other factors and other risks,
including those that we have described in our filings with the
Securities and Exchange Commission, including but not limited to
our Annual Report on Form 10-K, current reports on Form 8-K and our
quarterly reports on Form 10-Q. As a result, we can provide no
assurance that our future results will not be materially different
from those projected. Brooks expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
such statement to reflect any change in our expectations or any
change in events, conditions or circumstances on which any such
statement is based. Brooks undertakes no obligation to update the
information contained in this press release.
About Brooks Automation, Inc.
Brooks is a leading
provider of life science and semiconductor manufacturing automation
solutions worldwide. The Company applies its automation and
cryogenics expertise to provide a full suite of reliable cold-chain
sample management solutions across life sciences in areas such as
drug development, clinical research and advanced cell
therapies. Brooks recently added global capability for gene
sequencing and gene synthesis services through its strategic
acquisition of GENEWIZ, expanding its sample-based services
offerings. With over 40 years as a partner to the
semiconductor manufacturing industry, Brooks is a provider of
industry-leading precision robotics, integrated automation systems
and services. Brooks is headquartered in Chelmsford, MA, with operations in
North America, Europe and Asia. For more information,
visit www.brooks.com.
INVESTOR CONTACTS:
Mark Namaroff
Director, Investor Relations
Brooks Automation
978.262.2635
Mark.namaroff@brooks.com
Sherry Dinsmore
Brooks Automation
978.262.2400
sherry.dinsmore@brooks.com
John Mills
Partner
ICR, LLC
646.277.1254
john.mills@icrinc.com
BROOKS AUTOMATION,
INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(In thousands, except per share data)
|
|
|
Three Months Ended
|
|
|
Six Months
Ended
|
|
|
|
March 31,
|
|
|
March 31,
|
|
|
|
2019
|
|
2018
|
|
|
2019
|
|
2018
|
|
|
Revenue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Products
|
$
|
128,056
|
|
$
|
121,031
|
|
|
$
|
253,430
|
|
$
|
226,803
|
|
|
Services
|
|
70,334
|
|
|
35,921
|
|
|
|
124,327
|
|
|
72,748
|
|
|
Total
revenue
|
|
198,390
|
|
|
156,952
|
|
|
|
377,757
|
|
|
299,551
|
|
|
Cost of
revenue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Products
|
|
77,803
|
|
|
70,635
|
|
|
|
152,376
|
|
|
134,164
|
|
|
Services
|
|
40,071
|
|
|
23,931
|
|
|
|
72,785
|
|
|
48,742
|
|
|
Total cost of
revenue
|
|
117,874
|
|
|
94,566
|
|
|
|
225,161
|
|
|
182,906
|
|
|
Gross
profit
|
|
80,516
|
|
|
62,386
|
|
|
|
152,596
|
|
|
116,645
|
|
|
Operating
expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and
development
|
|
14,101
|
|
|
11,347
|
|
|
|
27,249
|
|
|
22,752
|
|
|
Selling, general and
administrative
|
|
52,373
|
|
|
40,671
|
|
|
|
105,914
|
|
|
78,599
|
|
|
Restructuring
charges
|
|
370
|
|
|
47
|
|
|
|
429
|
|
|
48
|
|
|
Total operating
expenses
|
|
66,844
|
|
|
52,065
|
|
|
|
133,592
|
|
|
101,399
|
|
|
Operating
income
|
|
13,672
|
|
|
10,321
|
|
|
|
19,004
|
|
|
15,246
|
|
|
Interest
income
|
|
316
|
|
|
356
|
|
|
|
739
|
|
|
504
|
|
|
Interest
expense
|
|
(8,018)
|
|
|
(2,196)
|
|
|
|
(13,308)
|
|
|
(4,377)
|
|
|
Loss on
extinguishment of debt
|
|
(9,051)
|
|
|
—
|
|
|
|
(9,051)
|
|
|
—
|
|
|
Other expenses,
net
|
|
(778)
|
|
|
(515)
|
|
|
|
(807)
|
|
|
(2,438)
|
|
|
Income (loss) before
income taxes
|
|
(3,859)
|
|
|
7,966
|
|
|
|
(3,423)
|
|
|
8,935
|
|
|
Income tax
benefit
|
|
(1,030)
|
|
|
(54,531)
|
|
|
|
(6,860)
|
|
|
(55,181)
|
|
|
Income (loss) from
continuing operations
|
|
(2,829)
|
|
|
62,497
|
|
|
|
3,437
|
|
|
64,116
|
|
|
Income from
discontinued operations, net of tax
|
|
6,250
|
|
|
4,523
|
|
|
|
14,399
|
|
|
19,390
|
|
|
Net income
|
$
|
3,421
|
|
$
|
67,020
|
|
|
$
|
17,836
|
|
$
|
83,506
|
|
|
Basic net income per
share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic net income (loss)
per share from continuing operations
|
$
|
(0.04)
|
|
$
|
0.89
|
|
|
$
|
0.05
|
|
$
|
0.91
|
|
|
Basic net income per
share from discontinued operations
|
|
0.09
|
|
|
0.06
|
|
|
|
0.20
|
|
|
0.28
|
|
|
Basic net income per
share
|
$
|
0.05
|
|
$
|
0.95
|
|
|
$
|
0.25
|
|
$
|
1.19
|
|
|
Diluted net income
per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted net income
(loss) per share from continuing operations
|
$
|
(0.04)
|
|
$
|
0.89
|
|
|
$
|
0.05
|
|
$
|
0.90
|
|
|
Diluted net income per
share from discontinued operations
|
|
0.09
|
|
|
0.06
|
|
|
|
0.20
|
|
|
0.27
|
|
|
Diluted net income
per share
|
$
|
0.05
|
|
$
|
0.95
|
|
|
$
|
0.25
|
|
$
|
1.18
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average
shares outstanding used in computing net income per
share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
72,077
|
|
|
70,220
|
|
|
|
71,760
|
|
|
70,340
|
|
|
Diluted
|
|
72,292
|
|
|
70,613
|
|
|
|
72,215
|
|
|
70,908
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BROOKS AUTOMATION,
INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)
|
|
|
March 31,
|
|
September 30,
|
|
2019
|
|
2018
|
|
(unaudited)
|
|
|
|
Assets
|
|
|
|
|
|
Current
assets
|
|
|
|
|
|
Cash and cash
equivalents
|
$
|
137,217
|
|
$
|
197,708
|
Marketable
securities
|
|
47
|
|
|
46,281
|
Accounts receivable,
net
|
|
163,653
|
|
|
125,192
|
Inventories
|
|
108,512
|
|
|
96,986
|
Prepaid expenses and
other current assets
|
|
35,056
|
|
|
31,741
|
Current assets held
for sale
|
|
65,005
|
|
|
66,148
|
Total current
assets
|
|
509,490
|
|
|
564,056
|
Property, plant and
equipment, net
|
|
97,939
|
|
|
59,988
|
Long-term marketable
securities
|
|
2,795
|
|
|
7,237
|
Long-term deferred tax
assets
|
|
28,012
|
|
|
43,798
|
Goodwill
|
|
492,526
|
|
|
255,876
|
Intangible assets,
net
|
|
270,793
|
|
|
99,956
|
Other
assets
|
|
23,250
|
|
|
5,294
|
Non-current assets
held for sale
|
|
63,072
|
|
|
59,052
|
Total
assets
|
$
|
1,487,877
|
|
$
|
1,095,257
|
Liabilities and
Stockholders' Equity
|
|
|
|
|
|
Current
liabilities
|
|
|
|
|
|
Current portion of
long-term debt
|
$
|
8,114
|
|
$
|
2,000
|
Accounts
payable
|
|
56,934
|
|
|
55,873
|
Deferred
revenue
|
|
31,200
|
|
|
25,884
|
Accrued warranty and
retrofit costs
|
|
7,202
|
|
|
6,340
|
Accrued compensation
and benefits
|
|
24,129
|
|
|
29,322
|
Accrued restructuring
costs
|
|
586
|
|
|
659
|
Accrued income taxes
payable
|
|
7,276
|
|
|
6,746
|
Accrued expenses and
other current liabilities
|
|
36,294
|
|
|
30,405
|
Current liabilities
held for sale
|
|
6,595
|
|
|
7,388
|
Total current
liabilities
|
|
178,330
|
|
|
164,617
|
Long-term
debt
|
|
535,384
|
|
|
194,071
|
Long-term tax
reserves
|
|
15,037
|
|
|
1,102
|
Long-term deferred tax
liabilities
|
|
15,978
|
|
|
7,135
|
Long-term pension
liabilities
|
|
4,717
|
|
|
4,255
|
Other long-term
liabilities
|
|
7,997
|
|
|
5,547
|
Non-current
liabilities held for sale
|
|
523
|
|
|
698
|
Total
liabilities
|
|
757,966
|
|
|
377,425
|
Stockholders'
Equity
|
|
|
|
|
|
Preferred stock, $0.01
par value - 1,000,000 shares authorized, no shares issued or
outstanding
|
|
—
|
|
|
—
|
Common stock, $0.01
par value - 125,000,000 shares authorized, 85,593,182 shares issued
and
72,131,313 shares outstanding at March 31, 2019,
84,164,130 shares issued and 70,702,261 shares
outstanding at September 30, 2018
|
|
856
|
|
|
841
|
Additional paid-in
capital
|
|
1,909,684
|
|
|
1,898,434
|
Accumulated other
comprehensive income
|
|
11,852
|
|
|
13,587
|
Treasury stock at cost
- 13,461,869 shares
|
|
(200,956)
|
|
|
(200,956)
|
Accumulated
deficit
|
|
(991,525)
|
|
|
(994,074)
|
Total stockholders'
equity
|
|
729,911
|
|
|
717,832
|
Total liabilities and
stockholders' equity
|
$
|
1,487,877
|
|
$
|
1,095,257
|
BROOKS AUTOMATION,
INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(In thousands)
|
|
Six Months
Ended
|
|
March 31,
|
|
2019
|
|
2018
|
Cash flows from
operating activities
|
|
|
|
|
|
Net income
|
$
|
17,836
|
|
$
|
83,506
|
Adjustments to
reconcile net income to net cash provided by operating
activities:
|
|
|
|
|
|
Depreciation and
amortization
|
|
26,339
|
|
|
17,634
|
Stock-based
compensation
|
|
9,717
|
|
|
10,129
|
Amortization of
premium on marketable securities and deferred financing
costs
|
|
556
|
|
|
217
|
Earnings of equity
method investments
|
|
(3,041)
|
|
|
(3,602)
|
Loss recovery on
insurance claim
|
|
—
|
|
|
(1,103)
|
Deferred income tax
benefit
|
|
(12,472)
|
|
|
(49,156)
|
Loss on extinguishment
of debt
|
|
9,051
|
|
|
—
|
Other gains on
disposals of assets
|
|
34
|
|
|
—
|
Accounts
receivable
|
|
(9,654)
|
|
|
(16,949)
|
Inventories
|
|
(9,992)
|
|
|
(16,233)
|
Prepaid expenses and
current assets
|
|
1,938
|
|
|
(17,248)
|
Accounts
payable
|
|
(6,088)
|
|
|
14,899
|
Deferred
revenue
|
|
5,410
|
|
|
(2,783)
|
Accrued warranty and
retrofit costs
|
|
740
|
|
|
(16)
|
Accrued compensation
and tax withholdings
|
|
(11,123)
|
|
|
(4,151)
|
Accrued restructuring
costs
|
|
(57)
|
|
|
(1,336)
|
Proceeds from recovery
on insurance claim
|
|
886
|
|
|
—
|
Accrued expenses and
current liabilities
|
|
2,149
|
|
|
9,619
|
Net cash provided by
operating activities
|
|
22,229
|
|
|
23,427
|
Cash flows from
investing activities
|
|
|
|
|
|
Purchases of property,
plant and equipment
|
|
(9,676)
|
|
|
(5,675)
|
Purchases of
marketable securities
|
|
(1,290)
|
|
|
(49,560)
|
Sales of marketable
securities
|
|
48,904
|
|
|
—
|
Maturities of
marketable securities
|
|
2,557
|
|
|
100
|
Acquisitions, net of
cash acquired
|
|
(442,704)
|
|
|
(64,988)
|
Proceeds from sales of
property, plant and equipment
|
|
—
|
|
|
200
|
Net cash used in
investing activities
|
|
(402,209)
|
|
|
(119,923)
|
Cash flows from
financing activities
|
|
|
|
|
|
Proceeds from term
loan, net of discount
|
|
686,386
|
|
|
197,554
|
Proceeds from issuance
of common stock
|
|
1,548
|
|
|
1,395
|
Payment of financing
costs
|
|
(687)
|
|
|
(318)
|
Repayment of term
loan
|
|
(352,289)
|
|
|
(500)
|
Repayment of capital
lease
|
|
(487)
|
|
|
—
|
Common stock dividends
paid
|
|
(14,429)
|
|
|
(14,125)
|
Net cash provided by
financing activities
|
|
320,042
|
|
|
184,006
|
Effects of exchange
rate changes on cash and cash equivalents
|
|
(553)
|
|
|
4,884
|
Net increase
(decrease) in cash and cash equivalents
|
|
(60,491)
|
|
|
92,394
|
Cash and cash
equivalents, beginning of period
|
|
197,708
|
|
|
101,622
|
Cash and cash
equivalents, end of period
|
$
|
137,217
|
|
$
|
194,016
|
Revision of Prior Period Financial Statements
During the three months ended March 31,
2019, the Company identified a misclassification related to
the presentation of the product and service revenue and the cost of
product and service revenue related to GENEWIZ in the Company's
Consolidated Statements of Operations for the three months ended
December 31, 2018. The total revenue
and cost of revenue related to GENEWIZ for the three months ended
December 31, 2018 were included in
the product revenue and cost of revenue line items instead of the
service revenue and cost of revenue line items in the Consolidated
Statements of Operations in the Form 10-Q for the quarter ended
December 31, 2018. GENEWIZ was
acquired during the three months ended December 31, 2018 and therefore the
misclassification did not impact any other historical
periods. The misclassification had no impact on total revenue
or the total cost of revenue, gross profit, operating income
(loss), net income (loss), as well as basic and diluted net income
(loss) per share during any of the periods presented. Additionally,
the misclassification had no impact on the Company's consolidated
balance sheets and consolidated statements of cash flows during any
of the prior periods. Please refer to Note 1 "Basis of
Presentation" to the Company's unaudited consolidated financial
statements included in the Form 10-Q for the quarter ended
March 31, 2019 for further
information on this reclassification.
The following table summarizes the effects of the
misclassification to the three months ended December 31, 2018:
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
December 31, 2018
|
Dollars in thousands
|
|
As Previously
Reported
|
|
Adjustment
|
|
As
Revised
|
Total
Company
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
|
|
|
|
|
|
|
|
Products
|
|
$
|
141,732
|
|
$
|
(16,357)
|
|
$
|
125,375
|
Service
|
|
|
37,636
|
|
|
16,357
|
|
|
53,993
|
Total
Revenue
|
|
|
179,368
|
|
|
—
|
|
|
179,368
|
|
|
|
|
|
|
|
|
|
|
Cost of
revenue
|
|
|
|
|
|
|
|
|
|
Products
|
|
|
83,481
|
|
|
(8,907)
|
|
|
74,574
|
Service
|
|
|
23,806
|
|
|
8,907
|
|
|
32,713
|
Total cost of
revenue
|
|
$
|
107,287
|
|
$
|
—
|
|
$
|
107,287
|
|
|
|
|
|
|
|
|
|
|
Brooks Life
Science Segment
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
|
|
|
|
|
|
|
|
Products
|
|
$
|
39,931
|
|
$
|
(16,357)
|
|
$
|
23,574
|
Service
|
|
|
26,730
|
|
|
16,357
|
|
|
43,087
|
Total
Revenue
|
|
$
|
66,661
|
|
$
|
—
|
|
$
|
66,661
|
|
|
|
|
|
|
|
|
|
|
Notes on Non-GAAP Financial Measures:
These financial measures are used in addition to and in
conjunction with results presented in accordance with GAAP and
should not be relied upon to the exclusion of GAAP financial
measures. Management adjusted the GAAP results for the impact of
amortization of intangible assets, restructuring charges, purchase
price accounting adjustments and charges related to M&A to
provide investors better perspective on the results of operations
which the Company believes is more comparable to the similar
analysis provided by its peers. Management also excludes
special charges and gains, such as impairment losses, gains and
losses from the sale of assets, as well as other gains and charges
that are not representative of the normal operations of the
business. In this context, the Company has also removed the effect
of reversing the valuation allowance reserve on the U.S. deferred
income tax assets. Management strongly encourages investors
to review our financial statements and publicly-filed reports in
their entirety and not rely on any single measure.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter Ended
|
|
|
March 31, 2019
|
|
December 31, 2018
|
|
March 31, 2018
|
|
|
|
|
per
diluted
|
|
|
|
per
diluted
|
|
|
|
per
diluted
|
Dollars in
thousands, except per share
data
|
|
|
|
share
|
|
|
|
share
|
|
|
|
share
|
Net income (loss)
from continuing operations
|
|
$
|
(2,829)
|
|
$
|
(0.04)
|
|
$
|
6,266
|
|
$
|
0.09
|
|
$
|
62,497
|
|
$
|
0.89
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchase accounting
impact on inventory and
contracts acquired
|
|
|
—
|
|
|
—
|
|
|
184
|
|
|
0.00
|
|
|
—
|
|
|
—
|
Amortization of
intangible assets
|
|
|
9,405
|
|
|
0.13
|
|
|
7,776
|
|
|
0.11
|
|
|
5,611
|
|
|
0.08
|
Restructuring
charges
|
|
|
370
|
|
|
0.01
|
|
|
59
|
|
|
0.00
|
|
|
47
|
|
|
0.00
|
Loss on extinguishment
of debt
|
|
|
9,051
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
Merger
costs
|
|
|
36
|
|
|
0.00
|
|
|
6,354
|
|
|
0.09
|
|
|
1,646
|
|
|
0.02
|
Adjustment of
valuation allowance against
deferred tax assets
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(58,018)
|
|
|
(0.82)
|
Tax Reform - rate
change applied to deferred tax
liabilities (1)
|
|
|
—
|
|
|
—
|
|
|
(1,125)
|
|
|
(0.02)
|
|
|
—
|
|
|
—
|
Tax adjustments
(2)
|
|
|
803
|
|
|
0.01
|
|
|
(4,411)
|
|
|
(0.06)
|
|
|
—
|
|
|
—
|
Tax effect of
adjustments
|
|
|
(4,593)
|
|
|
(0.06)
|
|
|
(3,184)
|
|
|
(0.04)
|
|
|
599
|
|
|
0.01
|
Non-GAAP adjusted
net income from continuing
operations
|
|
$
|
12,243
|
|
$
|
0.17
|
|
$
|
11,919
|
|
$
|
0.17
|
|
$
|
12,382
|
|
$
|
0.18
|
Stock
based compensation, pre-tax
|
|
|
5,121
|
|
|
0.07
|
|
|
4,176
|
|
|
0.06
|
|
|
5,074
|
|
|
0.07
|
Tax
rate
|
|
|
15
|
%
|
|
—
|
|
|
15
|
%
|
|
—
|
|
|
15
|
%
|
|
—
|
Stock-based
compensation, net of tax
|
|
|
4,353
|
|
|
0.06
|
|
|
3,550
|
|
|
0.05
|
|
|
4,313
|
|
|
0.06
|
Non-GAAP adjusted net
income excluding
stock-based compensation - continuing
operations
|
|
$
|
16,596
|
|
$
|
0.23
|
|
$
|
15,469
|
|
$
|
0.21
|
|
$
|
16,695
|
|
$
|
0.24
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares used in
computing non-GAAP diluted net
income per share
|
|
|
—
|
|
|
72,292
|
|
|
—
|
|
|
72,165
|
|
|
—
|
|
|
70,613
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months
Ended
|
|
|
March 31, 2019
|
|
March 31, 2018
|
|
|
|
|
per
diluted
|
|
|
|
per
diluted
|
Dollars in
thousands, except per share
data
|
|
$
|
|
share
|
|
$
|
|
share
|
Net income from
continuing operations
|
|
$
|
3,437
|
|
$
|
0.05
|
|
$
|
64,116
|
|
$
|
0.90
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchase accounting
impact on inventory and contracts acquired
|
|
|
184
|
|
|
0.00
|
|
|
1,160
|
|
|
0.02
|
Amortization of
intangible assets
|
|
|
17,180
|
|
|
0.24
|
|
|
11,103
|
|
|
0.16
|
Restructuring
charges
|
|
|
429
|
|
|
0.01
|
|
|
48
|
|
|
0.00
|
Loss on extinguishment
of debt
|
|
|
9,051
|
|
|
—
|
|
|
—
|
|
|
—
|
Merger costs
|
|
|
6,390
|
|
|
0.09
|
|
|
2,259
|
|
|
0.03
|
Adjustment of valuation
allowance against deferred tax assets
|
|
|
—
|
|
|
—
|
|
|
(58,018)
|
|
|
(0.82)
|
Tax Reform - rate
change applied to deferred tax liabilities
(1)
|
|
|
(1,125)
|
|
|
(0.02)
|
|
|
(671)
|
|
|
(0.01)
|
Tax adjustments
(2)
|
|
|
(3,608)
|
|
|
(0.05)
|
|
|
—
|
|
|
—
|
Tax effect of
adjustments
|
|
|
(7,777)
|
|
|
(0.11)
|
|
|
(1,321)
|
|
|
(0.02)
|
Non-GAAP adjusted
net income from continuing
operations
|
|
|
24,161
|
|
|
0.33
|
|
|
18,676
|
|
|
0.26
|
Stock-based
compensation, pre-tax
|
|
|
9,297
|
|
|
0.13
|
|
|
9,637
|
|
|
0.14
|
Tax
rate
|
|
|
15
|
%
|
|
—
|
|
|
15
|
%
|
|
—
|
Stock-based
compensation, net of tax
|
|
|
7,902
|
|
$
|
0.11
|
|
|
8,191
|
|
|
0.12
|
Non-GAAP adjusted net
income attributable to Brooks
Automation, Inc.- excluding stock-based compensation
|
|
$
|
32,063
|
|
$
|
0.44
|
|
$
|
26,867
|
|
$
|
0.38
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares used in
computing non-GAAP diluted net income
attributable to Brooks Automation, Inc. per share
|
|
|
—
|
|
|
72,215
|
|
|
—
|
|
|
70,908
|
(1)
|
Adjustments are
related to U.S. Federal Tax Reform.
|
|
|
(2)
|
The Company has
elected to apply the tax benefit related to the stock compensation
windfall realized in the quarter ended December 31, 2018 to the
non-GAAP full year tax rate and to exclude the benefit of a change
in the deferred tax benefit realized in the three months ended
December 31, 2018 related to a change in the Company's state
effective tax rate related to the acquisition of
GENEWIZ.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter Ended
|
|
Six Months
Ended
|
|
|
March 31,
|
|
December 31,
|
|
March 31,
|
|
March 31,
|
|
March 31,
|
Dollars in thousands
|
|
2019
|
|
2018
|
|
2018
|
|
2019
|
|
2018
|
GAAP net
income
|
|
$
|
3,421
|
|
$
|
14,415
|
|
$
|
67,020
|
|
$
|
17,836
|
|
$
|
83,506
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Less: Discontinued
operations
|
|
|
(6,250)
|
|
|
(8,149)
|
|
|
(4,523)
|
|
|
(14,399)
|
|
|
(19,390)
|
Less: Interest
income
|
|
|
(316)
|
|
|
(423)
|
|
|
(356)
|
|
|
(739)
|
|
|
(504)
|
Add: Interest
expense
|
|
|
8,018
|
|
|
5,290
|
|
|
2,196
|
|
|
13,308
|
|
|
4,377
|
Add: Income tax
provision (benefit)
|
|
|
(1,030)
|
|
|
(5,830)
|
|
|
(54,531)
|
|
|
(6,860)
|
|
|
(55,181)
|
Add:
Depreciation
|
|
|
5,099
|
|
|
4,060
|
|
|
3,304
|
|
|
9,159
|
|
|
6,140
|
Add: Amortization of
completed technology
|
|
|
2,791
|
|
|
2,007
|
|
|
982
|
|
|
4,798
|
|
|
1,886
|
Add: Amortization of
customer relationships
and acquired intangible assets
|
|
|
6,614
|
|
|
5,769
|
|
|
4,629
|
|
|
12,382
|
|
|
9,217
|
Add: Loss on
extinguishment of debt
|
|
|
9,051
|
|
|
—
|
|
|
—
|
|
|
9,051
|
|
|
—
|
Earnings before
interest, taxes, depreciation and
amortization
|
|
$
|
27,398
|
|
$
|
17,139
|
|
$
|
18,721
|
|
$
|
44,536
|
|
$
|
30,051
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter Ended
|
|
Six Months
Ended
|
|
|
March 31,
|
|
December 31,
|
|
March 31,
|
|
March 31,
|
|
March 31,
|
Dollars in thousands
|
|
2019
|
|
2018
|
|
2018
|
|
2019
|
|
2018
|
Earnings before
interest, taxes, depreciation and
amortization
|
|
$
|
27,398
|
|
$
|
17,139
|
|
$
|
18,721
|
|
$
|
44,536
|
|
$
|
30,051
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Less: Fair value
adjustment of equity method
investment
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
Add: Stock-based
compensation
|
|
|
5,121
|
|
|
4,176
|
|
|
5,074
|
|
|
9,297
|
|
|
9,637
|
Add: Restructuring
charges
|
|
|
370
|
|
|
59
|
|
|
47
|
|
|
429
|
|
|
48
|
Add: Purchase
accounting impact on inventory
and contracts acquired
|
|
|
—
|
|
|
184
|
|
|
—
|
|
|
184
|
|
|
1,160
|
Add: Merger
costs
|
|
|
36
|
|
|
6,354
|
|
|
1,646
|
|
|
6,390
|
|
|
2,259
|
Adjusted earnings
before interest, taxes,
depreciation and amortization
|
|
$
|
32,925
|
|
$
|
27,912
|
|
$
|
25,488
|
|
$
|
60,836
|
|
$
|
43,155
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter Ended
|
|
|
|
March 31, 2019
|
|
December 31, 2018
|
|
March 31, 2018
|
Dollars in
thousands
|
|
$
|
|
%
|
|
$
|
|
%
|
|
$
|
|
%
|
GAAP gross
profit/gross margin
percentage
|
|
$
|
80,516
|
|
40.6
|
%
|
|
$
|
72,081
|
|
40.2
|
%
|
|
$
|
62,386
|
|
39.7
|
%
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of
completed
technology
|
|
|
2,791
|
|
1.4
|
|
|
|
2,007
|
|
1.1
|
|
|
|
982
|
|
0.6
|
|
Purchase accounting
impact on
inventory and contracts acquired
|
|
|
—
|
|
0.0
|
|
|
|
184
|
|
0.1
|
|
|
|
—
|
|
0.0
|
|
Non-GAAP adjusted
gross
profit/gross margin percentage
|
|
$
|
83,307
|
|
42.0
|
%
|
|
$
|
74,272
|
|
41.4
|
%
|
|
$
|
63,368
|
|
40.4
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months
Ended
|
|
|
March 31, 2019
|
|
March 31, 2018
|
Dollars in
thousands
|
|
$
|
|
%
|
|
|
$
|
|
%
|
GAAP gross
profit/gross margin percentage
|
|
$
|
152,596
|
|
40.4
|
%
|
|
$
|
116,645
|
|
38.9
|
%
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of
completed technology
|
|
|
4,798
|
|
1.3
|
%
|
|
|
1,886
|
|
0.6
|
%
|
Purchase accounting
impact on inventory and
contracts acquired
|
|
|
184
|
|
0.0
|
%
|
|
|
1,160
|
|
0.4
|
%
|
Non-GAAP adjusted
gross profit/gross margin
percentage
|
|
$
|
157,578
|
|
41.7
|
%
|
|
$
|
119,691
|
|
40.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Brooks
Semiconductor Solutions Group
|
|
|
Quarter
Ended
|
Dollars in
thousands
|
|
March 31, 2019
|
|
December 31, 2018
|
|
March 31, 2018
|
GAAP gross
profit/margin percentage
|
|
$
|
45,987
|
|
40.7
|
%
|
|
$
|
45,915
|
|
40.7
|
%
|
|
$
|
43,457
|
|
40.1
|
%
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of
completed
technology
|
|
|
916
|
|
0.8
|
|
|
|
937
|
|
0.8
|
|
|
|
570
|
|
0.5
|
|
Purchase accounting
impact on
inventory and contracts acquired
|
|
|
—
|
|
—
|
|
|
|
184
|
|
0.2
|
|
|
|
—
|
|
—
|
|
Non-GAAP adjusted
gross
profit/margin percentage
|
|
$
|
46,903
|
|
41.6
|
%
|
|
$
|
47,036
|
|
41.7
|
%
|
|
$
|
44,027
|
|
40.6
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Brooks Life
Sciences
|
|
|
Quarter
Ended
|
Dollars in
thousands
|
|
March 31, 2019
|
|
December 31, 2018
|
|
March 31, 2018
|
GAAP gross
profit/margin percentage
|
|
$
|
34,529
|
|
40.4
|
%
|
|
$
|
26,166
|
|
39.3
|
%
|
|
$
|
18,929
|
|
39.0
|
%
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of
completed
technology
|
|
|
1,875
|
|
2.2
|
|
|
|
1,070
|
|
1.6
|
|
|
|
412
|
|
0.8
|
|
Purchase accounting
impact on
inventory and contracts acquired
|
|
|
—
|
|
—
|
|
|
|
—
|
|
—
|
|
|
|
—
|
|
—
|
|
Non-GAAP adjusted
gross
profit/margin percentage
|
|
$
|
36,404
|
|
42.6
|
%
|
|
$
|
27,236
|
|
40.9
|
%
|
|
$
|
19,341
|
|
39.8
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Brooks Semiconductor Solutions Group
|
|
|
|
|
Six Months
Ended
|
|
|
Dollars in
thousands
|
|
March 31, 2019
|
|
March 31, 2018
|
|
|
GAAP gross
profit/margin percentage
|
|
$
|
91,901
|
|
40.7
|
%
|
|
$
|
81,952
|
|
40.3
|
%
|
|
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of
completed technology
|
|
|
1,853
|
|
0.8
|
|
|
|
1,103
|
|
0.5
|
|
|
|
Purchase accounting
impact on inventory and
contracts acquired
|
|
|
184
|
|
0.1
|
|
|
|
—
|
|
—
|
|
|
|
Non-GAAP adjusted
gross profit/margin percentage
|
|
$
|
93,938
|
|
41.6
|
%
|
|
$
|
83,055
|
|
40.8
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Brooks Life
Sciences
|
|
|
|
|
Six Months
Ended
|
|
|
Dollars in
thousands
|
|
March 31, 2019
|
|
March 31, 2018
|
|
|
GAAP gross
profit/margin percentage
|
|
$
|
60,695
|
|
39.9
|
%
|
|
$
|
34,693
|
|
36.1
|
%
|
|
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of
completed technology
|
|
|
2,945
|
|
1.9
|
|
|
|
783
|
|
0.8
|
|
|
|
Purchase accounting
impact on inventory and
contracts acquired
|
|
|
—
|
|
—
|
|
|
|
1,160
|
|
1.2
|
|
|
|
Non-GAAP adjusted
gross profit/margin percentage
|
|
$
|
63,640
|
|
41.8
|
%
|
|
$
|
36,636
|
|
38.2
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Brooks Semiconductor Solutions Group
|
|
Brooks Life Sciences
|
|
Total
Segments
|
|
|
Quarter Ended
|
|
Quarter Ended
|
|
Quarter Ended
|
|
|
March 31,
|
|
December 31,
|
|
March 31,
|
|
March 31,
|
|
December 31,
|
|
March 31,
|
|
March 31,
|
|
December 31,
|
|
March 31,
|
Dollars in thousands
|
|
2019
|
|
2018
|
|
2018
|
|
2019
|
|
2018
|
|
2018
|
|
2019
|
|
2018
|
|
2018
|
GAAP operating
profit
|
|
$
|
17,987
|
|
$
|
16,141
|
|
$
|
15,424
|
|
$
|
3,143
|
|
$
|
1,590
|
|
$
|
1,496
|
|
$
|
21,130
|
|
$
|
17,731
|
|
$
|
16,920
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of
completed
technology
|
|
|
916
|
|
|
937
|
|
|
570
|
|
|
1,875
|
|
|
1,070
|
|
|
412
|
|
|
2,791
|
|
|
2,007
|
|
|
982
|
Purchase accounting
impact
on inventory and contracts
acquired
|
|
|
—
|
|
|
184
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
184
|
|
|
—
|
Non-GAAP adjusted
operating
profit
|
|
$
|
18,903
|
|
$
|
17,262
|
|
$
|
15,994
|
|
$
|
5,018
|
|
$
|
2,660
|
|
$
|
1,908
|
|
$
|
23,921
|
|
$
|
19,922
|
|
$
|
17,902
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
Segments
|
|
Corporate
|
|
Total
|
|
|
Quarter Ended
|
|
Quarter Ended
|
|
Quarter Ended
|
|
|
March 31,
|
|
December 31,
|
|
March 31,
|
|
March 31,
|
|
December 31,
|
|
March 31,
|
|
March 31,
|
|
December 31,
|
|
March 31,
|
Dollars in thousands
|
|
2019
|
|
2018
|
|
2018
|
|
2019
|
|
2018
|
|
2018
|
|
2019
|
|
2018
|
|
2018
|
GAAP operating profit
(loss)
|
|
$
|
21,130
|
|
$
|
17,731
|
|
$
|
16,920
|
|
$
|
(7,458)
|
|
$
|
(12,398)
|
|
$
|
(6,599)
|
|
$
|
13,672
|
|
$
|
5,333
|
|
$
|
10,321
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of
completed
technology
|
|
|
2,791
|
|
|
2,007
|
|
|
982
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
2,791
|
|
|
2,007
|
|
|
982
|
Amortization of
customer
relationships and acquired
intangible assets
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
6,614
|
|
|
5,769
|
|
|
4,629
|
|
|
6,614
|
|
|
5,769
|
|
|
4,629
|
Restructuring
charges
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
370
|
|
|
59
|
|
|
47
|
|
|
370
|
|
|
59
|
|
|
47
|
Purchase accounting
impact
on inventory and contracts
acquired
|
|
|
—
|
|
|
184
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
184
|
|
|
—
|
Merger costs
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
36
|
|
|
6,354
|
|
|
1,646
|
|
|
36
|
|
|
6,354
|
|
|
1,646
|
Non-GAAP adjusted
operating
profit (loss)
|
|
$
|
23,921
|
|
$
|
19,922
|
|
$
|
17,902
|
|
$
|
(438)
|
|
$
|
(216)
|
|
$
|
(277)
|
|
$
|
23,483
|
|
$
|
19,706
|
|
$
|
17,625
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Brooks Semiconductor Solutions Group
|
|
Brooks Life Sciences
|
|
Total
Segments
|
|
|
Six Months
Ended
|
|
Six Months
Ended
|
|
Six Months
Ended
|
Dollars in thousands
|
|
March 31, 2019
|
|
March 31, 2018
|
|
March 31, 2019
|
|
March 31, 2018
|
|
March 31, 2019
|
|
March 31, 2018
|
GAAP operating
profit
|
|
$
|
34,128
|
|
$
|
27,143
|
|
$
|
4,733
|
|
$
|
101
|
|
$
|
38,861
|
|
$
|
27,244
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of
completed technology
|
|
|
1,853
|
|
|
1,103
|
|
|
2,945
|
|
|
783
|
|
|
4,798
|
|
|
1,886
|
Purchase accounting
impact on
inventory and contracts acquired
|
|
|
184
|
|
|
—
|
|
|
—
|
|
|
1,160
|
|
|
184
|
|
|
1,160
|
Non-GAAP adjusted
operating profit
|
|
$
|
36,165
|
|
$
|
28,246
|
|
$
|
7,678
|
|
$
|
2,044
|
|
$
|
43,843
|
|
$
|
30,290
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
Segments
|
|
Corporate
|
|
Total
|
|
|
Six Months
Ended
|
|
Six Months
Ended
|
|
Six Months
Ended
|
Dollars in thousands
|
|
March 31, 2019
|
|
March 31, 2018
|
|
March 31, 2019
|
|
March 31, 2018
|
|
March 31, 2019
|
|
March 31, 2018
|
GAAP operating profit
(loss)
|
|
$
|
38,861
|
|
$
|
27,244
|
|
$
|
113,735
|
|
$
|
(11,998)
|
|
$
|
19,004
|
|
$
|
15,246
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of
completed technology
|
|
|
4,798
|
|
|
1,886
|
|
|
—
|
|
|
—
|
|
|
4,798
|
|
|
1,886
|
Amortization of
customer
relationships and acquired intangible
assets
|
|
|
—
|
|
|
—
|
|
|
12,382
|
|
|
9,217
|
|
|
12,382
|
|
|
9,217
|
Restructuring
charges
|
|
|
—
|
|
|
—
|
|
|
429
|
|
|
48
|
|
|
429
|
|
|
48
|
Purchase accounting
impact on
inventory and contracts acquired
|
|
|
184
|
|
|
1,160
|
|
|
—
|
|
|
—
|
|
|
184
|
|
|
1,160
|
Merger costs
|
|
|
—
|
|
|
—
|
|
|
6,390
|
|
|
2,259
|
|
|
6,390
|
|
|
2,259
|
Non-GAAP adjusted
operating profit
(loss)
|
|
$
|
43,843
|
|
$
|
30,290
|
|
$
|
132,936
|
|
$
|
(474)
|
|
$
|
43,187
|
|
$
|
29,816
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/brooks-automation-reports-results-of-second-fiscal-quarter-of-2019-ended-march-31-2019-and-announces-quarterly-cash-dividend-300840075.html
SOURCE Brooks Automation, Inc.